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In 2014, as a percentage of total stimulant dispensings, am-
phetamine-related products predominated in adults (83.6%
[488 322/583 885]), whereas methylphenidate was more com-
mon in youth (52.5% [247 710/472 248]) (data not shown).
Among those treated with stimulants, a clinician-reported ADHD
diagnosis was more common among youths than adults (62.0%
[40 055/64 626] vs 45.5% [33 790/74 269]) (data not shown).
Discussion | In a commercially insured population, in just 5 years,
between 2010 and 2014, the proportion of adults treated with
stimulants grew rapidly in contrast to youths, who had a mod-
est increase in stimulant use. The increase in adult stimulant use
maybelargelydrivenbyincreasesinoutpatientdiagnosesofadult
ADHD.3 However,consistentwithpreviousreports,4 weshowthat
a large proportion of stimulant-treated adults lacked an ADHD di-
agnosis, potentially reflecting off-label use. This raises concerns
regarding potential nonmedical use of prescription stimulants.5,6
The study limitations include dispensings that may not rep-
resent actual consumption and limited data on clinical appro-
priateness of treatment. Finally, the findings may not be na-
tionally representative. Nevertheless, our study reports a
prominent expansion in stimulant use among adults in a large,
commercially insured population and supports further re-
search to better understand outcomes of stimulant use, par-
ticularly among adult women.
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Association of Systemic Inflammation With Risk
of Completed Suicide in the General Population
There is a growing prima facie case for inflammation being
associated with suicide. In cohort studies,1 elevated levels
of inflammatory markers have been linked to the future
occurrence of depression, a known risk factor for suicide. In
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psychiatric patients, inflammation is positively associated
with the intensity of self-reported suicidal ideation,2 and
those who commit suicide have higher cytokine levels post
mortem relative to control patients.3 Furthermore, indi-
viduals with asthma, a condition characterized by inflam-
mation, experience higher rates of suicide mortality than
their nonatopic counterparts.4
While these various lines of evidence may implicate in-
flammation in the pathophysiology of suicide, there has been
no prospective examination of the link between inflamma-
tion and future suicide events.
Methods | Data were pooled from a series of independent, geo-
graphically representative, near-identical surveys of individu-
als living in private households, conducted from January 1998
to May 2007 in the United Kingdom.5 In 7 surveys (the 1998,
1999, 2003, 2004, and 2006 Health Surveys for England; the
1998 and 2003 Scottish Health Surveys), serum C-reactive pro-
tein (CRP) levels were ascertained using the N Latex CRP mono-
immunoassay on the Behring Nephelometer II analyzer (Dade
Behring). Study members were linked to national cause-of-
death registers until February 2011 for the Health Survey for En-
gland or December 2009 for the Scottish Health Survey. Death
certification for suicide has a high level of agreement with other
sources of evidence (eg, forensic reports, police reports, and
toxicological and histological data).6 Covariates included psy-
chological distress, which was determined by caseness (ie, a
score greater than 3) on the 12-item General Health Question-
naire, self-reported long-standing mental illness, and the use
of psychotropic medication. Ethical approval for each survey
Table. Association of C-Reactive Protein With Completed Suicidea
Adjustment
No. of
Events No. at Risk
CRP, HR (95% CI)b
P Value
1-SD. Increase in
CRP, HR (95% CI)cLow (<1 mg/L)
Intermediate
(1-3 mg/L) High (>3 mg/L)
No. of events/No. at risk 26 39 349 5/14 241 9/13 660 12/11 448 NA NA




26 37 392 1 [Reference] 2.09 (0.69-6.32) 3.86 (1.32-11.32) .01 1.50 (1.01-2.23)
Age-, sex-, and somatic
illness-adjusted
26 39 339 1 [Reference] 2.15 (0.71-6.50) 4.16 (1.42-12.18) .007 1.55 (1.04-2.29)
Age-, sex-, and psychological
distress-adjusted
25 38 114 1 [Reference] 2.60 (0.79-8.52) 4.56 (1.43-14.55) .008 1.53 (1.03-2.29)
Age-, sex- and
smoking-adjusted
26 39 200 1 [Reference] 1.83 (0.60-5.54) 3.03 (1.03-8.94) .04 1.36 (0.91-2.03)
Multivariable-adjustedd 25 36 267 1 [Reference] 2.23 (0.68-7.35) 3.31 (1.02-10.73) .04 1.33 (0.89-2.01)
Abbreviations: CRP, C-reactive protein (to convert to nanomoles per liter,
multiply by 9.524); HR, hazard ratio; NA, not applicable.
a Suicide mortality was denoted by any mention of the following events on
death certificates (International Classification of Diseases, Ninth Revision and
Tenth Revision): suicide and self-inflicted poisoning by solid or liquid
substances (E950-E959), injury undetermined whether accidentally or
purposely inflicted (E980-E989), terrorism (U03.1 and U03.9), intentional
self-harm (X60-X84), event of undetermined intent (Y10-Y34), sequelae of
intentional self-harm, assault and events of undetermined intent (Y87), and
sequelae of unspecified external cause (Y89.9).
b In all analyses, the baseline hazard function was stratified by study.
c For the computation of hazard ratios per 1-SD increase in CRP, CRP data were
log-transformed (1-SD change in log[CRP] = 1.25).
d Adjusted for age, sex, socioeconomic status, psychological distress, cigarette
smoking, and somatic illness (ie, neoplasms, diabetes, other endocrine
disorders, cerebrovascular disease, myocardial infarction, angina,
hypertension, any other heart disease, respiratory diseases, and any other
nonmental health condition).
Figure. Suicide Death Rates According to C-Reactive Protein (CRP) Level and Duration of Follow-up
No. at risk (No. of events)
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The proportion of deaths by suicide in
each of the 3 CRP categories (low [<1
mg/L], intermediate [1-3 mg/L], or
high [>3 mg/L]) over the duration of
follow-up (0-17 years). Each step
signals at least 1 death by suicide. To
convert to nanomoles per liter,
multiply by 9.524.
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was granted by local research ethics committees, and study
members provided informed consent at the time of the sur-
vey. Approval and informed consent were not required for the
present analyses.
Results | In an analytical sample of 39 349 participants with data
on inflammation, age, sex, and mortality, a mean (SD) duration
of 8.6 (3.3) years of follow-up gave rise to 26 deaths ascribed to
suicide (7.7 events per 100 000 person-years). Age- and sex-
adjusted hazard ratios (HRs) and 95% CIs were calculated for
study covariates; being a cigarette smoker (current vs never/for-
mer: HR, 9.67; 95% CI, 3.82-24.52), male (male vs female: HR,
2.64; 95% CI, 1.15-6.07), socioeconomically disadvantaged
(manual vs nonmanual social class: HR, 4.02; 95% CI, 1.60-10.13),
and psychologically distressed (score >3 vs ≤3: HR, 4.89; 95%
CI, 2.22-10.80) were associated with an elevated rate of suicide.
After basic adjustment, people in the highest inflammation
group were 4 times more likely to die by suicide relative to those
in the lowest group (HR, 4.20; 95% CI, 1.44-12.25) (Table). A
graded association was apparent across the 3 categories (P value
= .007), with a 1-SD increase in inflammation associated with
a 55% increase in suicide risk (HR, 1.55; 95% CI, 1.05-2.30). This
gradient was attenuated somewhat after adjustment for smok-
ing, although accounting for other covariates had little impact.
Excluding people at various thresholds of high CRP (ie, at
4, 6, 8, and 10 mg/L [to convert to nanomoles per liter, multi-
ply by 9.524]) did not materially alter our findings. While a posi-
tive association between CRP and suicide rates was apparent
across the full duration of follow-up (Figure), on partitioning (≤5
vs >5 years), the magnitude of this association was somewhat
stronger in the early phase (multivariable-adjusted HR for a 1-SD
increase in CRP: HR, 1.63; 95% CI, 0.87-3.05) relative to the later
phases (HR, 1.17; 95% CI, 0.69-1.96).
Discussion | We found up to a 4-fold increased risk of com-
pleted suicide in individuals with elevated levels of inflam-
mation compared with those with low levels. That this gradi-
ent was only partially explained by controlling for a series of
covariates raises the likelihood that other mechanisms under-
lie the association. Our finding that suicide was associated with
a series of known risk factors gives us some confidence in our
novel results for inflammation.
Conclusions | In conclusion, this is the first prospective cohort
study to examine the link between systemic inflammation and
future suicide risk, but it is not without its shortcomings. De-
spite a large sample size, the number of completed suicides
herein was modest, leading to low statistical power. Our re-
sults warrant testing using the present study design and other
approaches, such as mendelian randomization and large-
scale pharmacological trials of inflammation reduction.
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COMMENT & RESPONSE
Effects of Cannabis Use on Human Behavior:
A Call for Standardization of Cannabis Use Metrics
To the Editor With rapidly shifting legislation worldwide in re-
lation to recreational and medicinal cannabis use, the review
by Volkow et al1 is timely. We highlight several additional note-
worthy issues for consideration.
While further evidence has emerged that acute and long-
termexposuretocannabisimpairscognition,2 thereisstillgrossly
insufficient evidence for recovery of function with abstinence.
Neither the parameters of cannabis exposure nor the neural
mechanisms subserving persistence or recovery have been elu-
cidated. Well-controlled prospective studies monitoring resto-
ration of brain function and structure from current use through
prolonged abstinence are required to delineate the time course
and moderators of potential recovery of cognitive function.
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